Slusarczyk, Magdalena ORCID: https://orcid.org/0000-0002-4707-7190, Serpi, Michaela ORCID: https://orcid.org/0000-0002-6162-7910 and Pertusati, Fabrizio ORCID: https://orcid.org/0000-0003-4532-9101 2018. Phosphoramidates and phosphonamidates (ProTides) with antiviral activity. Antiviral Chemistry and Chemotherapy 26 , pp. 1-31. 10.1177/2040206618775243 |
Preview |
PDF
- Published Version
Available under License Creative Commons Attribution No Derivatives. Download (1MB) | Preview |
Abstract
Following the first report on the nucleoside phosphoramidate (ProTide) prodrug approach in 1990 by Chris McGuigan, the extensive investigation of ProTide technology has begun in many laboratories. Designed with aim to overcome limitations and the key resistance mechanisms associated with nucleoside analogues used in the clinic (poor cellular uptake, poor conversion to the 5′-monophosphate form), the ProTide approach has been successfully applied to a vast number of nucleoside analogues with antiviral and anticancer activity. ProTides consist of a 5′-nucleoside monophosphate in which the two hydroxyl groups are masked with an amino acid ester and an aryloxy component which once in the cell is enzymatically metabolized to deliver free 5′-monophosphate, which is further transformed to the active 5′-triphosphate form of the nucleoside analogue. In this review, the seminal contribution of Chris McGuigan’s research to this field is presented. His technology proved to be extremely successful in drug discovery and has led to two Food and Drug Administration-approved antiviral agents.
Item Type: | Article |
---|---|
Date Type: | Published Online |
Status: | Published |
Schools: | Pharmacy |
Publisher: | Nucleus Global |
ISSN: | 2040-2066 |
Date of First Compliant Deposit: | 31 May 2018 |
Date of Acceptance: | 13 May 2018 |
Last Modified: | 21 Oct 2024 11:16 |
URI: | https://orca.cardiff.ac.uk/id/eprint/111877 |
Citation Data
Cited 76 times in Scopus. View in Scopus. Powered By Scopus® Data
Actions (repository staff only)
Edit Item |